Citius Oncology, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Citius Oncology, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, an increase in shares for its stock incentive plan, and auditor ratification.
NASDAQ
Citius Oncology's majority stockholders approved an amendment to increase the company's authorized shares of common stock from 100 million to 400 million.
NASDAQ
Citius Oncology is set to increase its authorized shares of common stock from 100 million to 400 million following stockholder approval via written consent.